Air Products (NYSE:APD) is a world-leading industrial gases company in operation for over 80 years focused on serving energy, environmental, and emerging markets. The Company has two growth pillars driven by sustainability. Air Products’ base business provides essential industrial gases, related equipment and applications expertise to customers in dozens of industries, including refining, chemicals, metals, electronics, manufacturing, and food. The Company also develops, engineers, builds, owns and operates some of the world's largest clean hydrogen projects supporting the transition to low- and zero-carbon energy in the heavy-duty transportation and industrial sectors. Additionally, Air Products provides turbomachinery, membrane systems and cryogenic containers globally. The Company had fiscal 2023 sales of $12.6 billion from operations in approximately 50 countries and has a current market capitalization of about $65 billion. Approximately 23,000 passionate, talented and committed employees from diverse backgrounds are driven by Air Products’ higher purpose to create innovative solutions that benefit the environment, enhance sustainability and reimagine what's possible to address the challenges facing customers, communities, and the world.

At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising commitment and ideas that help our customers to help people. In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of. Our work makes A Meaningful Difference.

At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising commitment and ideas that help our customers to help people. In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of. Our work makes A Meaningful Difference.

We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Robertet S.A. was founded in Grasse in 1850 and is the world leader in natural products. Based in France and majority family-owned since its creation, the Robertet Group is still controlled by the Maubert family and is the only fragrance, flavour and ingredient company that is fully integrated throughout the entire creative process, from source to final fragrance or flavour. Today, the Robertet Group is represented in more than 50 countries, has more than 2,200 employees worldwide and offers its customers a range of more than 1,350 natural materials and products created in one of its 14 global creation centers. In 2022, the Robertet Group will have achieved a global net turnover in excess of 700 million euros. Natural raw materials Robertet supplies natural ingredients for the flavoring and perfume industries as well as the active ingredients used in health and beauty products. Its expertise ranges from sourcing plants to industrial processes of extraction, hydro-distillation, purification, and molecular distillation, as well as CO2 extraction, combining its methods and knowhow with tradition and innovation. Fragrances Through its staff of perfumers, researchers, evaluators, application and marketing specialists, Robertet explores the world of unique olfactory emotions and develops high quality perfumes. Flavors Since the Group has a thorough knowledge of the flavor cultures specific to each continent, its flavorists evaluate the ability of their creations to meet the customer’s requirements with the help of customized sensory panels. Active ingredients The Group’s new Health & Beauty Division is backed by the nutricosmetics of Hitex and Bionov to explore the health and beauty benefits of natural ingredients.

We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.

PFNonwovens (PFN) is a leading global producer of customized nonwoven fabrics. Our vision is to provide nonwoven fabrics with unrivalled levels of wellness and protection to improve people’s lives, while helping to build a more sustainable world. We make innovative high-value products for multiple key markets: Baby Care: delighting parents and babies alike Medical: protecting medical professionals Adult Incontinence & Fem Care: providing discreet protection and comfort Our mission is to lead in material innovation and break down barriers to sustainability. Our Nonwoven Fabric Innovators create high-performance and luxurious fabrics that improve quality of life, deliver exceptional value, and a brighter future for our planet. Our production teams combine state-of-the-art, high-skill manufacturing capabilities with a best-in-class quality mindset, and a customer-first-service culture. We continuously advance to create the future of nonwovens for personal care and healthcare industries. PFN has a dynamic workforce of over 1,100 team members. Headquartered in Prague, Czech Republic, we operate five production plants worldwide: two in the Czech Republic, and one each in the United States, Egypt, and South Africa. For more information, visit: www.pfnonwovens.com.

Borealis is one of the world’s leading providers of advanced and sustainable polyolefin solutions. In Europe, Borealis is also an innovative leader in polyolefins recycling and a major producer of base chemicals. We leverage our polymer expertise and decades of experience to offer value adding, innovative and circular material solutions for key industries such as consumer products, energy, healthcare, infrastructure and mobility. In re-inventing essentials for sustainable living, we build on our commitment to safety, our people, innovation and technology, and performance excellence. With head offices in Vienna, Austria, Borealis employs 6,000 employees and operates in over 120 countries. OMV, the Austria-based international energy, fuels & feedstock and chemicals & materials company, owns 75% of Borealis, while the remaining 25% is owned by Abu Dhabi National Oil Company, or ADNOC, based in the UAE. We supply services and products to customers around the globe through Borealis and two important joint ventures: Borouge and Baystar™. Netiquette We are happy to respond to your questions from Monday to Friday from 09:00–17:00 CET. Mutual respect is our basic principle on social media. Users are responsible for their contributions. Do not post anything that violates applicable law, the criminal code, the rights of others, in particular personal rights, copyrights, or trademark rights, racist, sexist, abusive or otherwise indecent content. At Borealis, we value open and transparent dialogue. Thus, we do not engage with anonymous users on our channels. We reserve the right to delete comments that are unrelated to the original post. Furthermore, we reserve the right to edit or delete content violating the above-mentioned rules. Business partners who would like to associate Borealis with their initiatives (mentions) are only permitted to do so after having received our prior consent. http://bit.ly/borealis-privacy

In 1959, entrepreneur Robert H. Dallas formed what was to become one of the larger privately-owned chemical companies in the United States. In 1989, a newly formed Dallas Group of America, Inc. was established as a spin-off and grew into a diversified manufacturer of basic and specialty chemicals. The Dallas Group produces the highest quality MAGNESOL® and DALSORB® synthetic magnesium silicates, ammonium chloride, ammonium sulfate, and lignosulfonates and serves customers in more than 100 countries. The company operates multiple manufacturing and packaging facilities in North America, China, and Europe. The Dallas Group’s laboratories are staffed with degreed chemists, engineers, and technicians performing more than 50,000 tests each year to ensure that all products and raw materials meet specifications for quality and purity. Selected staff routinely participate in the AOCS Approved Chemists Program and have been awarded Proficiency Program Winner status in AOCS’s NIOP Fats and Oils Program numerous times. Our production facilities are GMP-certified, ensuring that our products are consistently produced and controlled according to quality standards.

Piramal Critical Care (PCC), a business division of Piramal Pharma Limited (PPL) is one of the leaders in inhaled anesthetics and a global player in hospital generics. “Saving and improving patients’ lives” is much more than a purpose statement to us. We are motivated by our vision of commitment to delivering critical care solutions for patients and healthcare providers, while achieving sustainable and profitable growth for all the stakeholders. Piramal Critical Care maintains a wide presence across the US, Europe and more than 100 countries across the globe. Our product portfolio includes inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, injectable anti-infectives, oral therapy for Type I Gaucher and Niemann pick Type C disease, anticholinergic, plasma volume expander, non-depolarizing neuromuscular blocking agent, depolarizing skeletal muscle relaxant and an anxiolytic, sedative and pain medication. Our products include Sevoflurane, Desflurane, Isoflurane, Halothane, Gablofen® (Baclofen Injection), MITIGO™(Morphine Sulfate), Dipidolor® (Piritramide), Sublimaze® (Fentanyl Citrate), Rapifen® (Alfentanil Hydrochloride), Sufenta® (Sufentanil Citrate), Hypnomidate®(Etomidate), Ampicillin and Sulbactam for Injection, USP, Cefepime for Injection, USP, Ceftriaxone for Injection, USP, Linezolid Injection, Ampicillin for Injection, USP, Piperacillin and Tazobactam for Injection, USP, Yargesa™ (Miglustat), Glycopyrrolate, Haemaccel, Rocuronium Bromide Injection, Succinylcholine Chloride Injection, USP, Dexmedetomidine Injection, USP, Dexmedetomidine HCl in 0.9% Sodium Chloride Injection (RTU*) and Propofol- Lipuro emulsion for Injection or Infusion. PCC has strong manufacturing and process development experience. PCC has fully owned manufacturing facilities in Bethlehem, PA, USA and Digwal, India. Customer centricity is the cornerstone of our business. *RTU Ready to use

Recordati Rare Diseases Inc. (RRD) markets products to treat rare diseases. RRD is a member of the Recordati Group, which includes Recordati S.p.A., Orphan Europe, among other companies around the globe. The Recordati Group, which was established in 1926 currently employs more than 4,000 worldwide. The RRD mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.